A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated RejectionKatharina A. Mayer, Georg A. Böhmig, Susanne Haindl et al.|New England Journal of Medicine|2024Cited by 151
Serological Response to Three, Four and Five Doses of SARS-CoV-2 Vaccine in Kidney Transplant RecipientsBilgin Osmanodja, Eva Schrezenmeier|Journal of Clinical Medicine|2022Cited by 85
225.3: Randomized phase 2 trial of felzartamab in humoral transplant rejection.Katharina A. Mayer, Georg A. Böhmig, Eva Schrezenmeier et al.|Transplantation|2024Cited by 0